Project Grant K08NS140637
- Federal Project Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded the University of Pennsylvania a Project Grant totaling $215,350 on March 1, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). This award supports a research and career development initiative led by Dr. Jackson, an Assistant Professor of Neurosurgery at the University of Pennsylvania, through the project period ending...
- Federal Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded The Leland Stanford Junior University a Project Grant of $209,177 under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, effective February 1, 2026, with a completion date of January 31, 2031. The research project, "Targeting the MAP4K4 Pathway to Inhibit Pediatric High-Grade Glioma Invasion," focuses on identifying and...
- Federal Grant Award Summary The National Institute of Biomedical Imaging and Bioengineering awarded a K08 mentored career development grant of $194,022 to Massachusetts General Hospital (MGH) on August 1, 2025, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286). The award, which extends through July 31, 2029, supports the candidate's transition to independence as a translational oncologist by developing deep learning (DL)...
- Federal Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded The Johns Hopkins University a $773,607 Project Grant effective August 1, 2025 through July 31, 2027 under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. The award supports development of novel anthracycline-derivative drugs designed to penetrate the blood-brain barrier and treat diffuse midline glioma (DMG), a pediatric brain tumor with...
- Federal Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $224,265 Project Grant to the University of Pittsburgh effective August 1, 2025, through July 31, 2030, under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. This Career Development Award supports the development and testing of novel interventions to improve neurological prognostication for patients with hypoxic-ischemic brain injury...
- Federal Project Grant Award Summary The University of North Carolina at Chapel Hill received a Project Grant award of $229,078 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, effective August 11, 2025, with a completion date of July 31, 2030. This research initiative focuses on ferroptosis sensitization in glioblastoma, a highly aggressive form of brain cancer....
- Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded The Johns Hopkins University a Project Grant of $120,987.00 under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) on August 4, 2025. The grant supports basic neuroscience research conducted in Baltimore, Maryland, with a completion date of July 31, 2027. The research investigates the molecular mechanisms underlying interstitial axon branching in the mammalian...
- Federal Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded $478,980 to the University of California, San Francisco on August 13, 2025, under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. This five-year project grant supports the career development and research training of Dr. Sasha Gupta, a physician scientist, to establish her as an independently funded investigator in cellular therapeutics....
- Federal Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $499,516 Project Grant to The Leland Stanford Junior University, effective February 1, 2026 through January 31, 2031, under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. This research initiative develops a novel imaging strategy to optimize immunotherapy for brain tumors, specifically glioblastoma, by creating a first-in-class...
- Federal Project Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $610,554 Project Grant to The Trustees of Columbia University in the City of New York (Health Sciences Division) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. The award, effective August 1, 2025, through July 31, 2030, funds research investigating the mechanisms by which mammalian target of rapamycin (mTOR) and...
This K08 Mentored Career Development Award, totaling $214,101 and awarded March 6, 2026, supports translational neuroscience research conducted by an Assistant Professor of Neurosurgery at Johns Hopkins University. Funded through the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), the award provides advanced training in molecular biology, cancer metabolism, and novel drug delivery strategies to enable the principal investigator's transition toward independent investigator status. The research deliverables focus on developing and validating a novel therapeutic approach for glioblastoma, a devastating brain cancer with median survival of 13 months. The project employs MRI-guided focused ultrasound (MRIGFUS) technology to transiently disrupt the blood-brain barrier and enhance delivery of ME3BP7, a pyruvate analog targeting MCT1, a metabolic transporter overexpressed in over 80 percent of glioblastomas. Primary research objectives include elucidating ME3BP7's mechanism of action on MCT1-dependent metabolism and optimizing drug delivery across the blood-brain barrier using patient-derived xenograft models. The five-year project period (through February 28, 2031) will generate mechanistic insights and preclinical validation data to establish the clinical translatability of this metabolic targeting and drug delivery strategy under mentorship from an internationally recognized leader in brain tumor research.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $214.1k | 3/6/26 |